Recce Pharmaceuticals (ASX:RCE) reports positive safety data latest cohort in R327 trial
- Recce Pharmaceuticals (RCE) reports positive safety data in ten male subjects who received 4000mg of Recce’s R327 product as part of a first-phase clinical trial
- The subjects are part of the sixth cohort to be intravenously dosed with R327, and the 4000mg dose marks an 80-fold increase from the first cohort
- Recce says that based on today’s results, it expects an independent safety committee to recommend the commencement of recruitment for cohort seven
- The company says the study is on track to have all phase-one dosing completed by the second quarter of 2022
Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile
- Recce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy male subjects
- The company reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously dosed at 2,000 milligrams (mg)
- As such, an independent safety committee has unanimously approved the next cohort to begin dosing at 4,000mg, with subjects now recruited and dosing underway
- The company says the study is on track to have all phase one dosing complete by the second quarter of 2022
Recce Pharmaceuticals (ASX:RCE) advances phase one R327 trial to high dose level
- Recce Pharmaceuticals (RCE) is set to administer its “high dose” cohort following its successful phase one clinical trial of R327 in the “low dose” cohort
- The 10 healthy human subjects administered with R327 in the “low dose” cohort showed good safety and tolerability of the antibiotic at 1000mg
- The study is on track to have all phase one dosing complete by the end of Q2, 2022
- R327 is believed to be the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health
Hong Kong gives anti-viral patent nod to Recce Pharmaceuticals (ASX:RCE)
- Australia-based drug developer Recce Pharmaceuticals (RCE) granted a patent in Hong Kong for two of its synthetic polymer anti-infective drug candidates
- The patent is called the “Anti-Virus Agent and Method for Treatment of Viral Infection” and expires in February 2037
- The patent is for Recce’s R327 synthetic anti-infective drug and R529 anti-viral formulation
- With Hong Kong’s pharmaceutical market valued at about US$2.3 billion, Recce says the patent in Hong Kong marks another “endorsement for our commercial and clinical development strategy”
Recce Pharmaceuticals (ASX:RCE) reports positive safety data from fourth R327 trial cohort
- Recce Pharmaceuticals (RCE) reports positive safety results from the fourth patient cohort in a first-phase trial of its RECCE 327 (R327) synthetic anti-infective
- The drug developer dosed 10 healthy male subjects with 1000mg of R327 as part of the trial, with R327 indicated to be safe and well-tolerated in all subjects
- The 1000mg dose is a twenty-fold increase on the initial dose of 50mg given to the first patient cohort back in January
- An independent safety committee will now review the data from the fourth cohort of subjects to determine if the trial can move ahead to the next cohort
Recce Pharmaceuticals (ASX:RCE) given the go-ahead for next dose round in Phase 1 clinical study
- Recce Pharmaceuticals’ (RCE) new class of synthetic anti-infectives drug, the RECCE 327 (R327) has been given the go-ahead for the next set of doses by an Independent Safety Committee (ISC) following a successful Phase I intravenous (IV) clinical trial of 10 healthy human subjects
- The intravenous dose concluded that the drug demonstrated good safety and tolerability; the study evaluated R327 across eight sequential dosing cohorts of 50-16,000 milligrams in 7-10 healthy subjects per dose.
- R327 is the only clinical stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health
- The study is on track to have all Phase I dosing complete by Q2 2022
Recce Pharmaceuticals (ASX:RCE) doses final three patients in cohort three of R327 trial
- Recce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intravenous (IV) clinical trial of RECCE327 (R327)
- The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with doses ranging from 50 to 16,000 milligrams
- The three new patients received 500 milligrams of R327, with all 10 patients dosed so far indicating a good safety and tolerability profile
- Recruitment for the fourth cohort is underway and the study remains on track to have all phase I dosing completed by Q2 2022
Recce Pharmaceuticals (ASX:RCE) clinical trial progress points to safety of R327
- Recce Pharmaceuticals’ (RCE) phase-one intravenous clinical of R327 indicates a good safety and tolerability profile among seven healthy male subjects
- The company says its cohort three was tested with 500 mg of R327, which is designed for the treatment of serious and potentially life-threatening infections such as sepsis
- An independent safety committee will review the study post completion, which the company expects to be successful
- Recce CEO James Graham says the results of the trial represent a wonderful milestone for the company
Recce Pharmaceuticals (ASX:RCE) ends December quarter with $15.83m in cash
- Recce Pharmaceuticals (RCE) ended the December quarter with a cash balance of $15.83 million post research and development (R&D) costs of $1.54 million
- During the quarter, Recce reported positive data from its phase 1 and 2 clinical trial for the treatment of burn wound infections with its R327 technology
- The company also received approval and started phase 1 of an intravenous clinical trial for R327, with the first human cohort successfully dosed with 50 mg in December
- The company says with its strong financial position, it is well placed to continue to deliver upon its overall goals and objectives over the time ahead
Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial
- Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327)
- R327 is designed to treat serious bacterial infections including sepsis.
- The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327
- An independent safety committee has approved an increase in dosage to 500mg in the third cohort
Recce Pharmaceuticals (ASX:RCE) positive safety data from phase 1 clinical trial
- Recce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial for RECCE 327 (R327)
- R327 is designed to treat serious bacterial infections including sepsis
- In its first cohort of the phase one trial, nine healthy male subjects demonstrated R327’s safety and tolerability
- An independent safety committee has now approved an increase in dosage from 50 milligrams to 150 milligrams in the second cohort
- The study is on track to have all Phase I dosing complete by the second quarter of this year
Recce Pharmaceuticals (ASX:RCE) recruits patients for Phase 1 trial of R327
- Recce Pharmaceuticals (RCE) recruits the first cohort of patients for its Phase 1 intravenous clinical trial of its lead compound RECCE 327 (R327)
- The trial is an ascending dose, randomised, placebo-controlled, double-blind study evaluating the safety and pharmacokinetics of R327 in 10 healthy male subjects
- The lead compound is administered as a single dose via a one-hour IV infusion with all 80 subjects expected to be dosed by the end of H1 2022
- The first cohort will be dosed over two days starting on December 16 with the first set of safety subject data anticipated at the end of 2021
Recce Pharmaceuticals (ASX:RCE) spikes amid trial update
- Recce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the treatment of burn wound infections
- RCE reports broad spectrum antibiotic activity on bacterial burn wound infections with a visible infection reduction within 24 hours on all patients
- Additionally, all acute infections were cleared within 5 days, and chronic infections within 7 days, with clinicians able to reduce treatment window
- The study at Fiona Stanley Hospital in WA is ongoing, with the targeted patient enrolment expected by early 2022 — allowing for the full data set to be compiled
ABOUT US
An Emerging Global Leader in the New Generation of Anti-Infective Therapies
Recce Pharmaceuticals Ltd (ASX: RCE) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens.
RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatment that may be used repeatedly against a broad range of bacteria and viruses. RECCE® 529 is a new synthetic polymer formulation with indication against viruses.
Preclinical studies of RECCE® 327 indicates a fast acting, broad-spectrum antibiotic effective against Gram-positive and Gram-negative bacteria, including antibiotic resistant superbugs.
In 2017 RECCE® 327 was awarded Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval.
Recce Origin
Recce Pharmaceuticals was founded by Dr. Graham Melrose, a former Executive Director, and Head of Research at Johnson & Johnson Asia Pacific and Australia. Following his discovery of RECCE® 327 and RECCE® 529, Recce Pharmaceuticals has since expanded to include a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by bacterial and viral pathogens.
Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.
We have adopted this approach to anti-infectives, where they are designed to:
- Enter the human body,
- Find the infection and threat (deadly bacteria and viruses),
- Eliminate the threat
- Exit without being noticed (side effects)
Our Vision & Values
“To target the global health problem of superbugs”
Discover
New synthetic (polymer based) drugs are uniquely used for targeting major human health threats. With over 30 years of polymer experience, Dr Melrose and team are well placed to broaden Recce’s technical capabilities.
Patent
Patents are the value of any technology company and Recce Pharmaceuticals Ltd is no exception. With a track record of applying for a patent and it always being accepted, Recce is well positioned to continue expanding its wholly owned international patent portfolio.
Commercialise
As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is funded to pursue its drug development activities, starting with the world’s largest pharmaceutical market the USA – as regulated by the with the U.S. Food and Drug Administration. Recce’s capitalistic culture sees all technical endeavours focused around a commercial outcome.
VISIT WEBSITE: https://www.recce.com.au/
Recce Pharmaceuticals (ASX:RCE) reports positive safety data latest cohort in R327 trial
Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile
(ASX:RCE): A multi-billion-dollar sepsis solution?
RCE REPORTS POSITIVE RESULTS FROM R327 TRIALS
(ASX:RCE) clinical trial progress points to safety of R327
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) shares spike following results from the team’s Clinical Trial for the Treatment of Burn Wound Infections. James Graham, Recce CEO, discusses the exciting progress and what this means for shareholders
(ASX:RCE) receives ethics approval to begin R327 trial
Recce Pharmaceuticals (ASX:RCE) granted US patent
Recce Pharmaceuticals (ASX:RCE) begins clinical trials at Fiona Stanley Burns Unit.
Recce Pharmaceutics (ASX:RCE) begins patient dosing for clinical trial
Recce Pharmaceuticals RCE – their patented treatment taking on COVID, Sepsis & Burns
Recce Pharmaceuticals’ (ASX:RCE) anti-infective treatment effective against antibiotic-resistant pathogens
Interview with James Graham, Executive Director - Recee Pharmaceuticals
